Clusters of adipose-derived mesenchymal stem cells not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Dose: 1 x 10\^8 cells/1 mL/vial (10,000 clusters of adipose-derived mesenchymal stem cells)”In the company’s words, NCT04661644 on ClinicalTrials.gov
- Tested for
- Critical Limb Ischemia
- Main trialPhase 1/2
- “This clinical trial is designed as a Phase 1/2a clinical trial targeting patients with critical limb ischemia. The trial is composed of Phase 1 to assess the tolerability and safety and Phase 2a to assess the safety and efficacy of the investigational product(A cluster of adipose-derived mesenchymal stem cells (3D-A) (cluster of adipose- derived mesenchymal stem cells)) and proceeds in that order.”In the company’s words, NCT04661644 on ClinicalTrials.gov
Other drugs for Critical Limb Ischemia
- TemsirolimusMercator MedSystems, Inc. · Phase 3
- EtribnabdioneVivaCell Biotechnology España · Phase 2
- APACAplagon Oy · Phase 2
- BGC101Biogen · Phase 1/2
- StempeucelCell Biopeutics Resources Sdn Bhd · Marketed (Phase 4 trial)
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 22 Apr 2024 | Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients with Critical Limb Ischemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026